Bass Goes Fishing: Troubles Ahead for Pharma?

By Tom Engellenner Note: This article is adapted from a longer guest post on Forbes.com last week. To view the Forbes article click here. Inter partes review (IPR) is a process established by Congress to permit defendants in patent infringement suits to quickly and inexpensively challenge patents asserted against them in an administrative trial at … Continue reading Bass Goes Fishing: Troubles Ahead for Pharma?

PTAB’s Broadest Reasonable Interpretation Rule Survives Another Challenge (Barely)

By Tom Engellenner The Court of Appeals for the Federal Circuit denied Cuozzo Speed Technology LLC's petition for en banc rehearing of a February panel decision affirming the PTAB's use the so-called broadest reasonable interpretation (BRI) standard in claim construction. The decision to refuse en banc rehearing was a 6-5 decision with Chief Judge Prost … Continue reading PTAB’s Broadest Reasonable Interpretation Rule Survives Another Challenge (Barely)

Post-Grant Challenges In Life Sciences: A Midyear Assessment

By Raymond A. Miller and N. Nicole Stakleff The America Invents Act established inter partes review and post-grant reviews mechanisms to challenge the validity of issued United States patents. These procedures were created to improve patent quality, and were introduced in part because of perceived abusive enforcement by nonpracticing entities in the consumer electronics space. As with … Continue reading Post-Grant Challenges In Life Sciences: A Midyear Assessment